Artisan International Value Fund Q1 2026 Portfolio Update

Nearly two-thirds of the portfolio's stocks fell during the quarter, and almost half declined by more than 10%, indicating broad weakness in positioning. Samsung Electronics, the largest holding, pre-released Q1 results showing significant growth in its core semiconductor business, but the biggest drags on performance were ICON, Unilever, and UBS. Overall tone is cautious as portfolio losses outweighed the positive Samsung update.

Analysis

The portfolio pain is more telling than the headline weighting: a broad drawdown with only a handful of idiosyncratic bright spots usually means factor exposure, not stock selection, dominated the quarter. That sets up a second-order issue for the laggards: once underperformance becomes crowded, the next leg is often driven by forced de-risking and PM-style benchmark preservation rather than fundamentals, which can keep multiples compressed even if estimates stop falling.

ICON looks most vulnerable to a “good company, bad setup” dynamic. In a risk-off tape, healthcare services and contract-research names can de-rate quickly when investors prioritize cash conversion and lower execution risk; if rates stay sticky, the market will keep discounting longer-dated earnings, making any recovery slower than the operating data would suggest. UL is more exposed to a different problem: consumer staples become a hiding place only until pricing power visibly fades, so any margin disappointment can trigger an abrupt rotation into food/household peers with cleaner volume trends.

UBS is the highest-beta name to sentiment and technicals here because its rerating depends on capital-markets activity and wealth-management stability, both of which are tightly linked to risk assets. If equity and credit volatility stay elevated for another 1-2 quarters, the market is likely to question how much operating leverage is really embedded in the current setup. The contrarian case is that Samsung’s semiconductor strength may be an early signal that the broad earnings backdrop is about to improve; if that propagates through hardware and cyclicals over the next 2-3 months, the current portfolio underperformance could reverse faster than consensus expects.

Key Decisions for Investors

• Maintain/establish a tactical short ICON versus a basket of defensive healthcare tools for 4-8 weeks; thesis is that multiple compression can outrun any near-term estimate stability. Cover on any guidance upside or broader biotech/healthcare re-rating.
• Prefer a relative-value short UL versus a consumer-staples peer with stronger volume momentum for the next 1-2 quarters; reward is valuation mean reversion if margin pressure persists, but stop out if pricing/mix data turns positive.
• Trim or hedge UBS exposure into any further rally in European financials over the next 1-2 months; use upside calls only if you want convexity to a risk-on rebound, because outright equity exposure is still highly sentiment-sensitive.
• For a contrarian expression, buy a 2-3 month call spread on a semiconductor or hardware proxy tied to improving supply-chain demand, funded by selling upside in the weakest laggard in the portfolio; this expresses the idea that Samsung’s read-through may broaden before the market fully prices it.